Sort
64,565 grants matching “drug discovery”
Multi-site longitudinal Integrated Neurocognitive and Sleep-Behavior Profiler for the Endophenotypic Classification of Dementia Subtypes (INSPECDS)
$999,922Chris Berka · Advanced Brain Monitoring, Inc. · R44 · FY2022 · AG
Targeting Tumor-Derived exRNA-Containing Microvesicles by High Throughput Screeni
$999,920Asim B Abdel-Mageed · Tulane University Of Louisiana · UH3 · FY2016 · TR
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists
$999,917Richard Scott Struthers · Crinetics Pharmaceuticals, Inc. · R44 · FY2013 · DK
Targeting Tumor-Derived exRNA-Containing Microvesicles by High Throughput Screeni
$999,911Asim B Abdel-Mageed · Tulane University Of Louisiana · UH3 · FY2017 · TR
Pre-clinical development of NGP 555 for the prevention of AD
$999,911William T Comer · Neurogenetic Pharmaceuticals, Inc. · U44 · FY2013 · NS
SBIR Phase II: AI-assisted identification of small molecules for targeted repair of vascular barrier dysfunctions
$999,878Mario Dipaola · Akttyva Therapeutics, Inc. · · FY2024 · TIP
National Drug Early Warning System Coordinating Center (NDEWS)
$999,866Linda B Cottler · University Of Florida · U01 · FY2025 · DA
A Chicago Biomedical Consortium Hub of Innovative Technologies for Entrepreneurship and Science (CBC - HITES)
$999,859Satish N Nadig · Northwestern University At Chicago · U01 · FY2025 · GM
A Chicago Biomedical Consortium Hub of Innovative Technologies for Entrepreneurship and Science (CBC - HITES)
$999,855Satish N Nadig · Northwestern University At Chicago · U01 · FY2024 · GM
Isolating novel fungi for antibiotic discovery
$999,832Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2011 · AI
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis
$999,781Brett E Crawford · Zacharon Pharmaceuticals, Inc. · R44 · FY2012 · NS
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
$999,744Mark Lim · Ambergen, Inc · R44 · FY2019 · CA
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
$999,744Mark Lim · Ambergen, Inc · R44 · FY2020 · CA
Development of a novel Alzheimer's disease therapeutic targeting tau
$999,721Glenn Larsen · Aquinnah Pharmaceuticals, Inc. · R44 · FY2024 · AG
A Continuous Manufacturing Platform for Complex Dosage Forms
$999,719Diane Jane Burgess · University Of Connecticut Storrs · U01 · FY2018 · FD
A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease
$999,713Kiarash Emami · Polarean, Inc. · R44 · FY2017 · HL
Pre-clinical development of NGP 555 for the prevention of AD
$999,681William T Comer · Neurogenetic Pharmaceuticals, Inc. · U44 · FY2012 · NS
Drug Repurposing Screening for Zika Virus Infection
$999,652Wei Zheng · National Center For Advancing Translational Sciences · ZIA · FY2020 · TR
CICI: RSARC: SECTOR: Building a Secure and Compliant Cyberinfrastructure for Translational Research
$999,651Yan Luo · University Of Massachusetts Lowell · · FY2017 · CSE
Drug Discovery from Slow Growing and Rare Microbial Species
$999,651Amy Lynn Spoering · Novobiotic Pharmaceuticals, Llc · R44 · FY2013 · AI
Toward a Mechanism-Based Approach to Treating Cardiac Arrhythmia
$999,600Bjorn C Knollmann · Vanderbilt University Medical Center · R35 · FY2024 · HL
OTHER FUNCTIONS SBIR PHASE II TOPIC 290 "RNAI SYNTHETIC LETHAL SCREEN IN CANCER
$999,596Alexandr Chenchik · Cellecta, Inc. · N44 · FY2012 · CA
Isolating novel actinomycetes for antibiotic discovery
$999,586Losee Lucy Ling · Novobiotic Pharmaceuticals, Llc · R44 · FY2011 · AI
Preclinical development of teixobactin, a new antibiotic
$999,567Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R44 · FY2020 · AI
Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis
$999,559Michelle M. Butler · Microbiotix, Inc · R44 · FY2019 · AI